Aims In order to anticipate drug-interactions of potential clinical significance the ability of the novel antidepressant, venlafaxine, to inhibit CYP2D6 dependent imipramine and desipramine 2-hydroxylation was investigated in human liver microsomes. The data obtained were compared with the selective serotonin re-uptake inhibitors, fluoxetine, sertraline, fluvoxamine and paroxetine. Venlafaxine's potential to inhibit several other major P450s was also studied (CYP3A4, CYP2D6, CYP1A2). Methods K i values for venlafaxine, paroxetine, fluoxetine, fluvoxamine and sertraline as inhibitors of imipramine and desipramine 2-hydroxylation were determined from Dixon plots of control and inhibited rate data in human hepatic microsomal incubations. The inhibitory effect of imipramine and desipramine on liver microsomal CYP2D6 dependent venlafaxine O-demethylation was determined similarly. Venlafaxine's IC 50 values for CYP3A4, CYP1A2 CYP2C9 were determined based on inhibition of probe substrate activities (testosterone 6b-hydroxylation, ethoxyresorufin O-dealkylase and tolbutamide 4-hydroxylation, respectively). Results Fluoxetine, paroxetine, and fluvoxamine were potent inhibitors of imipramine 2-hydroxylase activity (K i values of 1.6±0.8, 3.2±0.8 and 8.0±4.3 mm, respectively; mean±s.d., n=3), while sertraline was less inhibitory (K i of 24.7±8.9 mm). Fluoxetine also markedly inhibited desipramine 2-hydroxylation with a K i of 1.3±0.5 mm. Venlafaxine was less potent an inhibitor of imipramine 2-hydroxylation (K i of 41.0±9.5 mm) than the SSRIs that were studied. Imipramine and desipramine gave marked inhibition of CYP2D6 dependent venlafaxine O-demethylase activity (K i values of 3.9±1.7 and 1.7±0.9 mm, respectively). Venlafaxine did not inhibit ethoxyresorufin O-dealkylase (CYP1A2), tolbutamide 4-hydroxylase (CYP2C9) or testosterone 6b-hydroxylase (CYP3A4) activities at concentrations of up to 1 mm. Conclusions It is concluded that venlafaxine has a low potential to inhibit the metabolism of substrates for CYP2D6 such as imipramine and desipramine compared with several of the most widely used SSRIs, as well as the metabolism of substrates for several of the other major human hepatic P450s.
Introduction N-demethylation, as well as a combination of N-and O-demethylation, with N,O-didesmethylvenlafaxine rep-
Venlafaxine is a new antidepressant that is being used in the treatment of various depressive disorders. Unlike the resenting about 16% of the dose excreted in urine [1] .
We have demonstrated in a previous study [3] that ODV serotonin selective re-uptake inhibitors (SSRIs), venlafaxine's mechanism of pharmacological action is unique in that it formation is catalysed by human hepatic CYP2D6. CYP3A4 was tentatively identified in the same study as the protein involves the inhibition of the neuronal uptake of serotonin, noradrenaline and, to a lesser degree, dopamine. Venlafaxine responsible for catalysing the N-demethylation pathway. As a consequence of metabolism by CYP2D6, venlafaxine undergoes extensive hepatic metabolism, with O-demethylation the major route of metabolism in man [1] . Over 55% competitively inhibits the activity of this enzyme.
Comparative studies of the inhibitory effects of venlafaxine of a single oral dose of venlafaxine is excreted in the urine as O-demethylvenlafaxine (ODV) and its glucuronide on CYP2D6 compared with several widely used SSRIs (fluoxetine, paroxetine, fluvoxamine and sertraline) demonmetabolite (ODV-glucuronide [1] ). The receptor binding profile and effects on neurotransmitter uptake of ODV are strated that the SSRIs were approximately 10-300 fold more potent CYP2D6 inhibitors (K i values, 0.065-1.8 mm) than venlafaxine (K i , 20.0 mm [3] ). Of the SSRIs, only and inhibitor of CYP2D6 [4, 5] . While among the SSRIs Research Institute, Toronto, Canada. Fluvoxamine and paroxetine (S,R-enantiomer) were available in-house. fluoxetine is one of the most potent inhibitors of CYP2D6 [3, 6] , this compound appears to be a relatively poor Imipramine, desipramine and mianserin were purchased from Sigma Chemicals (St Louis, MO, USA). CYP2D6 substrate [7] . In vitro studies have also demonstrated that norfluoxetine, which is the major metabolite of 2-Hydroxyimipramine and 2-hydroxydesipramine were obtained from Derse and Schroeder (Madison, Wisconsin, fluoxetine in man [8, 9] , is also a potent inhibitor of this enzyme [7, 10] . USA). 4-Hydroxytolbutamide was from Ultrafine Chemicals (Salford, UK). 6b-Hydroxytestosterone was purchased from Inhibition of CYP2D6 by several of the SSRIs has been shown to have clinical consequences. For example, fluoSteraloids (Wilton, NH, USA). Ethoxyresorufin and resorufin was purchased from Molecular Probes (Eugene, OR, xetine, paroxetine and sertraline significantly interact with the metabolism of desipramine, due to the effect of these USA). All other reagents that were used were of the highest grade commercially available and were obtained from the agents on CYP2D6 dependent desipramine 2-hydroxylation [6, 11, 12, 13] . Elevated tricyclic antidepressant levels that usual sources. occur as a result of this interaction have been associated with toxic side effects such as seizures, delirium and Human livers arrhythmias [14] .
Fluoxetine also causes clinically relevant drug interactions Portions of snap-frozen human liver from six donors were obtained from the International Institute for the due to inhibition of P450 enzymes other than CYP2D6, as evidenced by the finding that this agent impairs the Advancement of Medicine (IIAM, Exton, PA, USA). metabolism of alprazolam, which is thought to be a substrate for CYP3A4, both in vitro and in vivo [15] . Likewise, in
Preparation of microsomes and microsomal protein P450 content addition to inhibition of CYP2D6 [3] , fluvoxamine is also a selective inhibitor of CYP1A2, providing the mechanistic Human liver microsomes were prepared by differential ultracentrifugation according to standard procedures [19] . basis for the drug interactions and resulting toxicities that have been reported when this agent is coadministered
Microsomes were stored at −80°C until use. Microsomal protein content and P450 content was determined using the clinically with the CYP1A2 substrate theophylline [16, 17, 18] .
procedures of Bradford [20] and Omura & Sato [21], respectively. In light of the known effects of several SSRIs on tricyclic antidepressant metabolism discussed above, the primary goal of this study was to directly assess venlafaxine's potential to Enzyme and drug assays inhibit CYP2D6 dependent desipramine and imipramine 2-hydroxylation in in vitro human hepatic microsomal Desipramine and imipramine 2-hydroxylase activity Human liver microsomal incubations contained imipramine or incubations relative to several of the most widely prescribed SSRIs (fluoxetine, paroxetine, fluvoxamine, sertraline).
desipramine (15 mm for IC 50 studies [both substrates] and 5-25 mm for kinetic inhibition studies [both substrates]), Inhibitory potency was assessed by measuring enzymeinhibitor affinity constants (K i ). In addition, K i values for microsomal protein (1 mg), MgC1 2 (4 mm) and an NADPH regenerating system consisting of NADP (2 mg ml −1 ), imipramine and desipramine as inhibitors of CYP2D6 dependent O-desmethylvenlafaxine formation were also glucose-6-phosphate (2 mg ml −1 ) and glucose-6-phosphate dehydrogenase (0.8 units ml −1 ), in a total incubation determined, in microsomal incubations in which venlafaxine was examined as the drug substrate. volume of 0.5 ml of 0.1 m sodium phosphate buffer (pH 7.4). Incubations (25 min) were performed in a shaking While venlafaxine is a CYP2D6 inhibitor, its effects on the catalytic activity of the other major human P450s is not water bath, and were initiated by addition of the NADPH regenerating system (60 ml). Under these incubation conknown. Therefore, the second goal of this study was to further define the inhibitory potential of venlafaxine in ditions, preliminary studies demonstrated that product formation (2-hydroxydesipramine or 2-hydroxyimipramine) regard to human P450s other than CYP2D6, thereby allowing us to anticipate drug-drug interactions of potential was linear with respect to incubation time and microsomal protein concentration. Reactions were terminated by placing clinical relevance based on knowledge of alternate substrates for the affected P450 enzyme(s).
the incubation tubes on ice and extracting with 3 ml of ether/dichloromethane (60540) following addition of 5 mg of mianserin as an internal standard. The organic extract was Methods evaporated to dryness under a stream of nitrogen gas. Dried extracts were refrigerated at 4°C before h.p.l.c. analysis (see Chemicals below), which was usually on the following day. were performed in a shaking water bath, and were initiated by addition of the NADPH regenerating system (60 ml). in human microsomes, with CYP2D6 representing the high affinity component [22] , a preliminary study was performed Preliminary studies established that O-desmethylvenlafaxine formation was linear with respect to protein concentration to confirm these findings and identify the substrate concentration range required to assay CYP2D6 activity in our and incubation time under these incubation conditions. Reactions were terminated by placing tubes on ice and experiments. In this preliminary work, the rate of imipramine 2-hydroxylation was determined over a wide substrate adding ammonium hydroxide (14.5 m; 50 ml). Incubates were extracted with diethylether (5 ml, 10 min) following concentration range (1-1000 mm) and the data analyzed graphically by the Eadie-Hofstee method. Identical studies the addition of 1 mg of WY-45818 as an internal standard. Ether extracts were evaporated to dryness under a stream of were also performed with desipramine as the substrate. nitrogen gas. Dried extracts were stored at 4°C before h.p.l.c. analysis (see below).
IC 50 determinations IC 50 values for fluoxetine and venlafaxine were determined to obtain an initial semi-quantitative estimate of inhibitory potency in order to facilitate the Preparation of 2-hydroxyimipramine, 2-hydroxydesipramine and O-desmethylvenlafaxine standard curves Metabolite selection of inhibitor concentrations to be used in subsequent quantitative enzyme kinetic studies (see below). Appropriate standard curves were generated by adding known amounts of metabolites (2- IC 50 values were also determined for imipramine and taken through the entire incubation and extraction procedure followed by h.p.l.c. analysis (see below).
desipramine as inhibitors of venlafaxine O-demethylation. In these studies, venlafaxine (30 mm) was incubated with Standard curves were generated by plotting the metabolite (2-hydroxyimipramine, 2-hydroxydesipramine, Ovarying concentrations of imipramine or desipramine (both 0-500 mm). IC 50 values were estimated graphically from a desmethylvenlafaxine) to internal standard (mianserin or WY-45818) peak area ratio, against the amount of added plot of % control (uninhibited) activity against inhibitor concentration. metabolite.
H.p.l.c. analysis of 2-hydroxyimipramine, 2-hydroxy-
Enzyme kinetic inhibition studies The rate of 2-hydroxylation of imipramine or desipramine was assessed over a range of desipramine and O-desmethylvenlafaxine H.p.l.c. analyses of extracts of microsomal incubations with imipramine, desiprasubstrate concentrations (imipramine, desipramine; both 0-25 mm) in the presence and absence of varying conmine and venlafaxine were performed on a Waters h.p.l.c. system consisting of a solvent pump (model 625), autosampler centrations of venlafaxine or fluoxetine (0-80.0 mm and 0-5.0 mm, respectively). Concentrations of setraline, fluvox-(model 717) and system controller (model 600E). Dry microsomal extracts were dissolved in 50-100 ml of acetoamine and paroxetine used to determine the K i values of these agents as inhibitors of imipramine 2-hydroxylation nitrile/sodium phosphate buffer ( pH 3.0; 50550) immediately prior to h.p.l.c. analysis, and 35-50 ml was injected were 0-75 mm, 0-50 mm and 0-50 mm, respectively. The effect of imipramine and desipramine (0-7.5 mm) on the onto the chromatograph. Separations were performed on a Phenomenex Prodigy ODS2 reversed phase column rate of venlafaxine O-demethylation (0-30 mm) was assessed similarly. Apparent enzyme-substrate affinity constants and (250×4.6 mm; 5 mm). Samples were eluted under isocratic conditions, using a mobile phase consisting of 0.05 m sodium maximal reaction velocities (K m and V max , respectively) were calculated using an enzyme kinetics computer program phosphate buffer (pH 3.0) and acetonitrile (imipramine and desipramine, 66533; venlafaxine, 70530) at a flow rate of (Grafit, Erithacas Software Ltd, Staines, UK). Inhibition constants (apparent K i values) were estimated graphically by 0.6 ml min , respectively. contained testosterone (100 mm), an NADPH regenerating Fluoxetine markedly inhibited both imipramine and system and microsomal protein (1 mg ) in a total incubation desipramine 2-hydroxylation with IC 50 values for the volume of 1 ml of potassium phosphate buffer (pH 7.4).
inhibition of the two activities of 1.1 and 0.8 mm, respectively Incubations (10 min at 37°C) were initiated by the addition (Figure 1a and 1b) . Over the same concentration range, of NADPH. Reactions were terminated by placing tubes venlafaxine was only moderately inhibitory (about 20% for on ice. Following addition of an internal standard (corticosboth activities). terone, 2 mg), 6b-hydroxytestosterone formation was quantQuantitative enzyme kinetic inhibition studies revealed ified following extraction by h.p.l.c. analysis according to a that the mean apparent K i for sertraline, fluvoxamine, published procedure [31] .
paroxetine, fluoxetine and venlafaxine as inhibitors of imipramine 2-hydroxylation approximated from Dixon Tolbutamide 4-hydroxylase activity Microsomal incubations plots of the enzyme inhibition data was 24.7±8.9 mm, contained tolbutamide (200 mm), an NADPH regenerating 8.0±4.3 mm, 3.2±0.8 mm, 1.6±0.8 mm and 41.0±9.5 mm, system and hepatic microsomes (1 mg) in a total incubation respectively (n=3, Table 1 ). volume of 0.25 ml of 0.1 m potassium phosphate buffer
The mean apparent K i for fluoxetine as an inhibitor of ( pH 7.4). Incubations (60 min at 37°C), were terminated desipramine 2-hydroxylation estimated from Dixon plots by acidification with 1n HCl (100 ml). Following addition was 1.3±0.5 mm (n=3, Table 1 ). Dixon plots of the of chlorpropamide (0.5 mg ) as an internal standard, samples corresponding data for venlafaxine were curvi-linear and were extracted with diethyether (3 ml, 20 min). Extracts consequently the K i value and mode of inhibition for were dried under a stream of nitrogen gas and reconstituted venlafaxine could not be accurately determined. in h.p.l.c. mobile phase (100 ml; see below) prior to h.p.l.c.
analysis. H.p.l.c. separations were performed on a C-18
Inhibition of human microsomal venlafaxine O-demethylation reversed phase column (150 mm×4.6 mm; 5 mm) using the same h.p.l.c. system described above for analysis of the by imipramine and desipramine 2- . Peaks were monitored by on-line u.v. detimipramine and desipramine as inhibitors of venlafaxine Oection at 240 nm. 4-Hydroxytolbutamide was quantified demethylation were 1.6 and 0.9 mm, respectively ( Figure 2 ). from an appropriate standard curve.
The corresponding K i values for imipramine and desipramine approximated from Dixon plots of kinetic inhibition data IC 50 determinations Human microsomal ethoxyresorufin Owere 3.9±1.7 and 1.7±0.9 mm, respectively (n=3, Table 1 ). dealkylase, tolbutamide 4-hydroxylase and testosterone 6b-hydroxylase activities were determined in the presence and absence of varying concentrations of venlafaxine Inhibition of ethoxyresorufin O-dealkylase (CYP1A2), (10-1000 mm). IC 50 s were determined graphically from a testosterone 6b-hydroxylase (CYP3A4) and tolbutamide plot of % of control (uninhibited) activity against venlafaxine 4-hydroxylase (CYP2C9) concentration.
Venlafaxine was a poor inhibitor of ethoxyresorufin Odealkylase, testosterone 6b-hydroxylase and tolbutamide Results 4-hydroxylase in human microsomal incubations (IC 50 s for all three activities were >1000 mm; Figure 3 ). Fluoxetine
Kinetics of imipramine and desipramine 2-hydroxylation
was not evaluated for its effects on these enzyme activities. In preliminary experiments with pooled human liver microsomes in which the rate of 2-hydroxyimipramine Discussion formation was studied over a wide concentration range (1-1000 mm), the kinetics of imipramine 2-hydroxylase
In accord with our earlier work [3] , the data presented in the current study have demonstrated that fluoxetine, could be resolved into two components; one of high affinity, low capacity (approximate K m 12.9 mm, V max , 70.7 pmol fluvoxamine and paroxetine are potent inhibitors of human microsomal CYP2D6, while sertraline is less inhibitory. Also min −1 mg −1 ) and the other of low affinity, high capacity (approximate K m 43.4 mm, V max , 103.9 pmol min −1 mg −1 ; consistent with our earlier work was the finding that venlafaxine was a less potent CYP2D6 inhibitor than the data not shown). Over the same concentration range, the kinetics of desipramine 2-hydroxylation were monophasic (sertraline) to 26 fold (fluoxetine) more potent inhibitors of to CYP2D6 may be involved. Unlike for imipramine 2-hydroxylation, these enzymes may have similar kinetic this activity than venlafaxine. However, in the current study we found sertraline, as well as the other SSRIs that were constants, and therefore only become discernable when the CYP2D6 dependent component is inhibited (in this case by examined, to be less inhibitory (e.g. K i for sertraline 24.7 mm) than we had noted previously using dextromethorvenlafaxine). Consistent with this hypothesis, Brosen et al.
[12] have noted induction in the 2-hydroxylation of phan as the in vitro probe CYP2D6 substrate (K i for sertraline 1.2 mm [3] ). Similar substrate dependent differences desipramine in CYP2D6 poor metabolizers when patients of this phenotype are administered paroxetine. in K i values for the SSRIs as inhibitors of CYP2D6 have been reported in the literature. For example, sertraline's K i
The finding that fluoxetine and paroxetine were noncompetitive inhibitors of CYP2D6 dependent imipramine for the inhibition of CYP2D6 been reported as 22.7 mm or 0.7 mm when desipramine and sparteine are the respective metabolism was at variance with our previous work [3] , and the findings of others [22] , in which these agents have been CYP2D6 substrates [32, 33] . Higher K i values with desipramine as the substrate may be because a component characterized as competitive CYP2D6 inhibitors. The reason for this difference is unknown, but as noted above, this may of 2-hydroxylation is catalysed by enzymes in addition to CYP2D6. This conclusion is supported by the finding that relate to the involvement of enzymes other than CYP2D6 in the 2-hydroxylation of both of these antidepressants. In the kinetics of imipramine 2-hydroxylation were biphasic, as reported elsewhere [22] . In contrast, in the current study this regard, it is also noteworthy that the rank order of inhibitory potency among the compounds studied the kinetics of desipramine 2-hydroxylation appeared monophasic. However, in the presence of venlafaxine the kinetics differed in the current study (fluoxetine>paroxetine> fluvoxamineIsertraline>venlafaxine) relative to our of desipramine 2-hydroxylation were curvilinear suggesting that, as for imipramine 2-hydroxylation, enzymes in addition earlier work [3] in which dextromethorphan was the of imipramine by fluoxetine, paroxetine and fluvoxamine observed in this study, and by others [22, 32, 34] , is believed to be the mechanistic basis for the drug-drug interactions that occur when imipramine or desipramine are co-administered with these SSRIs in the clinical setting [11, 12, 35, 36] . The relatively high K i for venlafaxine as an inhibitor of CYP2D6 suggests that a significant drug interaction due to the concomitant administration of venlafaxine with these tricyclic antidepressants, as well as other CYP2D6 substrates, is less likely. Sertraline also inhibits tricyclic antidepressant metabolism in vivo, although consistent with its lesser in vitro inhibitory effects [6] , the magnitude of the interaction is small compared with the corresponding effect of fluoxetine [6, 11] . In rationalizing sertraline's lesser effect on desipramine metabolism in vivo compared with fluoxetine, Preskorn et al. [6, 11] have recently argued that this finding is due to the combination of sertraline's lower CYP2D6 inhibitory potency, shorter half-life (making it less likely to accumulate in the plasma and at the CYP2D6 active site in the liver) and lower plasma levels relative to fluoxetine. Extending , 21 ng ml −1 [37] ; fluoxetine, 20 mg day −1 , 85 ng ml −1 [40] ; sertraline, 50 mg day −1 , 25 ng ml −1 [41] ) suggests that venlafaxine has a lower CYP2D6 interaction potential than fluoxetine and sertraline. It is also noteworthy that norfluoxetine (the major metabolite of fluoxetine in man [8, 9] ) is present in the plasma at similar levels as parent drug after multiple dosing [39] . This metabolite has a long plasma half-life (7-15 days [40] ), and is equipotent in regard to CYP2D6 inhibition [7, 10] . Hence, enzyme inhibition can persist for some time after discontinuation of fluoxetine. By comparison, O-desmethylvenlafaxine has a significantly shorter half-life (10.4 h [36] ) and does not appear to inhibit CYP2D6 [3] . These differing characteristics of the major metabolites of venlafaxine and fluoxetine with respect to their disposition and CYP2D6 inhibitory potency further support the prediction that venlafaxine's effects on CYP2D6 in vivo is small relative to fluoxetine. The finding that imipramine and desipramine were of inhibition of O-desmethylvenlafaxine formation as evidenced by the low apparent K i values for imipramine and probe substrate (paroxetine>fluoxetine>sertraline> fluvoxamineIvenlafaxine). This difference may be because desipramine (3.9 and 1.7 mm, respectively) suggests that both tricyclic compounds have the potential to inhibit venlafaxine some of these compounds inhibit enzymes in addition to CYP2D6 (e.g. fluoxetine is also a CYP3A4 inhibitor), and O-demethylation in vivo. The finding that venlafaxine does not inhibit CYP2C9 these enzymes may also play a role in imipramine metabolism.
and CYP1A2 activity in vitro suggests that drug interactions between alternate substrates for these enzymes and venlafaxThe inhibition of CYP2D6 dependent 2-hydroxylation selective inhibitor of serotonin uptake. Med Res Rev 1990; 11: ine may not occur. However, it should be borne in mind 17-34. that in these studies we did not assess the relative affinities when these SSRIs are coadministered with imipramine, as 23-31. well as other CYP2D6 substrates, are less likely to occur
